Sonoma Pharmaceuticals, Inc. (SNOA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Quarterly

0 2.5M 5M 7.5M Q2 '22: 3.7M Q3 '22: 2.9M Q4 '22: 2.3M Q1 '23: 4M Q2 '23: 3.3M Q3 '23: 2.9M Q4 '23: 3M Q1 '24: 3.4M Q2 '24: 2.7M Q3 '24: 3.1M Q4 '24: 3.4M Q1 '25: 3.4M Q2 '25: 3.6M Q3 '25: 3.6M Q4 '25: 3.8M Q1 '26: 4M Q2 '26: 5.6M Q3 '26: 4.3M Q4 '26: 5.6M Q1 '27: 6.4M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit Quarterly

0 900K 1.8M 2.7M Q2 '22: 1.2M Q3 '22: 1.2M Q4 '22: 96K Q1 '23: 1.6M Q2 '23: 1.5M Q3 '23: 831K Q4 '23: 864K Q1 '24: 1.2M Q2 '24: 990K Q3 '24: 1.5M Q4 '24: 1.1M Q1 '25: 1.3M Q2 '25: 1.4M Q3 '25: 1.3M Q4 '25: 1.5M Q1 '26: 1.5M Q2 '26: 2.1M Q3 '26: 1.6M Q4 '26: 2.2M Q1 '27: 2.6M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '22: -964K Q3 '22: -958K Q4 '22: -3.1M Q1 '23: -855K Q2 '23: -731K Q3 '23: -1.8M Q4 '23: -1.1M Q1 '24: -1.2M Q2 '24: -1.2M Q3 '24: -844K Q4 '24: -1.4M Q1 '25: -1.2M Q2 '25: -850K Q3 '25: -1M Q4 '25: -656K Q1 '26: -1.1M Q2 '26: -337K Q3 '26: -678K Q4 '26: -351K Q1 '27: -40K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income Quarterly

-3M -1.5M 0 1.5M 3M 4.5M Q2 '22: -100K Q3 '22: -944K Q4 '22: -2.9M Q1 '23: -887K Q2 '23: -1M Q3 '23: -1.9M Q4 '23: -1.3M Q1 '24: -1.4M Q2 '24: -1.5M Q3 '24: -866K Q4 '24: -1.1M Q1 '25: -1.1M Q2 '25: -610K Q3 '25: -928K Q4 '25: -776K Q1 '26: -1.2M Q2 '26: -534K Q3 '26: -819K Q4 '26: -581K Q1 '27: -330K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue Quarterly

0 1.5M 3M 4.5M Q2 '22: 2.5M Q3 '22: 1.7M Q4 '22: 2.2M Q1 '23: 2.3M Q2 '23: 1.8M Q3 '23: 2.1M Q4 '23: 2.1M Q1 '24: 2.2M Q2 '24: 1.7M Q3 '24: 1.7M Q4 '24: 2.3M Q1 '25: 2.1M Q2 '25: 2.2M Q3 '25: 2.3M Q4 '25: 2.2M Q1 '26: 2.6M Q2 '26: 3.5M Q3 '26: 2.7M Q4 '26: 3.4M Q1 '27: 3.8M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Cash Flow Quarterly

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q2 '22: -1.3M Q3 '22: -326K Q4 '22: -1.4M Q1 '23: -1.5M Q2 '23: -1.8M Q3 '23: -348K Q4 '23: -2.4M Q1 '24: -215K Q2 '24: -1.2M Q3 '24: -1.1M Q4 '24: 152K Q1 '25: -912K Q2 '25: 354K Q3 '25: 565K Q4 '25: -95K Q1 '26: -2M Q2 '26: -635K Q3 '26: -764K Q4 '26: -519K Q1 '27: -649K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow Quarterly

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q1 '22: -1.3M Q2 '22: -1.3M Q3 '22: -327K Q4 '22: -1.5M Q1 '23: -1.6M Q2 '23: -1.9M Q3 '23: -379K Q4 '23: -2.6M Q1 '24: -232K Q2 '24: -1.2M Q3 '24: -1.1M Q1 '25: -917K Q2 '25: 328K Q3 '25: 563K Q4 '25: -142K Q1 '26: -2.1M Q2 '26: -645K Q3 '26: -811K Q4 '26: -548K Q1 '27: -651K Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q3 '25 Q2 '26 Q1 '27

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 2M 4M 6M Q2 '20: 1.3M Q1 '21: 1.8M Q2 '21: 2.2M Q3 '21: 2.1K Q1 '22: 2.1M Q2 '22: 2.3K Q3 '22: 3.1K Q1 '23: 3.1K Q2 '23: 3.1K Q3 '23: 3.1M Q1 '24: 4.9M Q2 '24: 258K Q3 '24: 546K Q1 '25: 851K Q2 '25: 1M Q3 '25: 1.5M Q1 '26: 1.6M Q2 '26: 1.6M Q3 '26: 1.7M Q1 '27: 3.8M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '18: -2.79 Q4 '19: -13.27 Q1 '20: -7.74 Q2 '20: -4.73 Q3 '20: -3.08 Q4 '20: -2.20 Q1 '21: -2.61 Q2 '21: -1.63 Q2 '24: -6.94 Q3 '24: -7.91 Q4 '24: -10.63 Q1 '25: -11.68 Q2 '25: -6.52 Q3 '25: -5.56 Q4 '25: -2.95 Q1 '26: -2.37 Q2 '26: -2.10 Q3 '26: -1.95 Q4 '26: -1.89 Q1 '27: -1.22 Q4 '19 Q3 '20 Q2 '21 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.